Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Stetson

Ophthalmology New York, NY Medical Doctor

NPI 1487603411 CMS profile 21438

15 W 44Th St, New York, NY 10036

Open in the dashboard

General payments

$6,603

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Stetson of New York, NY is reported in the CMS Open Payments database as having received $6,603 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $750 16
2024 General $505 12
2023 General $974 26
2022 General $1,110 38
2021 General $977 32
2020 General $289 10
2019 General $1,997 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Stetson
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Steven Stetson were reported at $750. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Steven Stetson Ophthalmology median Middle half National median
2019 $1,997 $258 $104–$655 $163
2020 $289 $126 $45–$321 $114
2021 $977 $205 $76–$534 $132
2022 $1,110 $266 $100–$678 $149
2023 $974 $308 $117–$745 $160
2024 $505 $340 $127–$846 $164
2025 $750 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Glaukos Corporation $1,068 11 payments
  2. Nidek Incorporated $1,000 1 payment
  3. Sun Pharmaceutical Industries Inc. $953 48 payments
  4. Oyster Point Pharma, Inc. $561 17 payments
  5. Kala Pharmaceuticals, Inc. $362 17 payments
  6. Johnson & Johnson Surgical Vision, Inc. $303 4 payments
  7. Novartis Pharmaceuticals Corporation $286 19 payments
  8. Bausch & Lomb Americas Inc. $266 13 payments
  9. Sight Sciences, Inc. $257 4 payments
  10. Bausch & Lomb, a division of Bausch Health US, LLC $242 11 payments
  11. Other $1,305 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,603 177 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
Products named General payments · program years 2019–2025
  1. Cequa $905 46 payments
  2. BromSite $397 25 payments
  3. EYSUVIS $362 17 payments
  4. INVELTYS $362 17 payments
  5. Xelpros $338 25 payments
  6. TYRVAYA $325 9 payments
  7. CE-marked KXLA system $240 3 payments
  8. KXL System $213 3 payments
  9. Photrexa $213 3 payments
  10. KXL system (not refurbished) $206 1 payment
  11. Other $4,264 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record